Robert Lowsky
Publications
- Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation. Clin Immunol. 2013; (1): 124-35
- Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood. 2012; (25): 6145-54
- Rare cells predict GVHD. Blood. 2012; (21): 4820-1
- Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant. 2012; (4): 581-8
- Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant. 2012; (5): 1133-45
- Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; (11): 1679-87
- Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation. Blood. 2011; (19): 5319-29
- Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Bone Marrow Transplant. 2011; (2): 192-9
- Translational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction. Semin Immunol. 2011; (4): 273-81
- Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia. Br J Haematol. 2010; (5): 637-9
- Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. Bone Marrow Transplant. 2010; (2): 303-9
- NKT cells, Treg, and their interactions in bone marrow transplantation. Eur J Immunol. 2010; (7): 1862-9
- Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. Biol Blood Marrow Transplant. 2010; (8): 1145-54
- Nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin: an update. Curr Opin Hematol. 2009; (6): 460-5
- TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 2009; (5): 1099-109
- Total lymphoid irradiation for graft-versus-host disease protection. Curr Opin Oncol. 2009: S23-6
- Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med. 2008; (4): 362-8
- High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2006; (7): 703-11
- A technique of bone marrow collection from vertebral bodies of cynomolgus macaques for transplant studies. J Surg Res. 2005; (2): 280-8
- CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Exp Hematol. 2005; (3): 279-85
- Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Blood. 2005; (6): 2300-6
- Protective conditioning for acute graft-versus-host disease. N Engl J Med. 2005; (13): 1321-31
- Approaches to transplantation tolerance in humans. Transplantation. 2004; (6): 932-6
- Short tandem repeat analysis to monitor chimerism in macaca fascicularis. Am J Transplant. 2004; (9): 1543-8

